

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. – 18. (Canceled)

19. (Currently amended) A method for diagnosis or therapy of tumours or a vascular proliferation disease in a patient comprises administering an antibody with specific, high affinity for the ED-B domain of fibronectin having a VH domain with the following amino acid sequence:

VH domain (SEQ ID NO: 30)

EVQLLES GGG	LVQP GGS LRL	SCAAS GFTFS
SFSMS WVRQA	PGKGL EWVSS	ISGSS GTTTY
ADSVK GRFTI	SRDNS KNTLY	LQMNS LRAED
TAVYY CAKPF	PYFDY WGQGT	LVT VSS

and having a VL domain with the amino acid sequence encoded by the VL domain encoding DNA of the DNA insert of ATCC deposit no. PTA-9529.[[.]]

20. (Previously presented) A conjugate comprising (a) an antibody with specific, high affinity for the ED-B domain of fibronectin having a VH domain with the following amino acid sequence:

VH domain (SEQ ID NO: 30)

EVQLLES GGG	LVQP GGS LRL	SCAAS GFTFS
SFSMS WVRQA	PGKGL EWVSS	ISGSS GTTTY
ADSVK GRFTI	SRDNS KNTLY	LQMNS LRAED

T A V Y Y C A K P F

P Y F D Y W G Q G T

L V T V S S

and having a VL domain with the amino acid sequence encoded by the VL domain encoding DNA of the DNA insert of ATCC deposit no. PTA-9529; and (b) a molecule capable of inducing blood coagulation and blood vessel occlusion.

21. (Previously presented) A conjugate according to claim 20 wherein the molecule capable of inducing blood coagulation and blood vessel occlusion is a photoactive molecule.

22. (Previously presented) A conjugate according to claim 21 wherein the photoactive molecule is a photosensitizer.

23. (Previously presented) A conjugate according to claim 22 wherein the photosensitizer absorbs at a wavelength above 600 nm.

24. (Currently Amended) A conjugate according to claim 22 wherein the photosensitizer is a derivative of tin (IV) chlorine[[e]] e6.

25. (Previously presented) A conjugate according to claim 20 wherein the molecule capable of inducing blood coagulation and blood vessel occlusion is a radionuclide.

26. (Previously presented) A conjugate according to claim 25 wherein the radionuclide is a  $\beta$ - emitting radionuclide.

27. (Canceled)

28. (Previously presented) A conjugate according to claim 20 comprising a molecule capable of inducing blood coagulation and blood vessel occlusion which is a photosensitizer and a molecule which is a radionuclide.

29. (Previously presented) A method for the treatment of an angiogenesis-related pathology in a patient comprising administering a conjugate according to claim 20.

30. (Previously presented) A method for the treatment of an angiogenesis-related pathology in a patient comprising administering a conjugate according to claim 22 by injection, followed by irradiating said patient.

31. (Previously presented) A method according to claim 30 wherein the angiogenesis-related pathology treated is caused by or associated with ocular angiogenesis.

32. (Previously presented) A method for the treatment of an angiogenesis-related pathology comprising administering a radionuclide-containing conjugate according to claim 25 by injection.

33. (Previously presented) A method according to claim 32 wherein the radionuclide is astatine-211.

34. (Previously presented) A method for the treatment of an angiogenesis-related pathology comprising administering a conjugate according to claim 28 by injection.

35. (Canceled)

36. (Previously presented) A conjugate of claim 20 wherein the antibody further comprises a linking sequence with the amino acid sequence encoded by the linker-encoding DNA of the DNA insert of ATCC deposited no. PTA-9529.

37. (Previously presented) A conjugate of claim 36 wherein the antibody is radiolabeled.

38. (Previously presented) A conjugate of claim 37 wherein the antibody is radioiodinated.
39. (Previously presented) A conjugate of claim 36 wherein the antibody is an ScFv antibody.
40. (Previously presented) A conjugate of claim 39 wherein the antibody is produced recombinantly.
41. (Previously presented) A conjugate of claim 36 wherein the ED-B domain of fibronectin is a human ED-B domain.
42. (Previously presented) A conjugate of claim 36 wherein the antibody is monoclonal.
43. (Previously presented) A diagnostic kit comprising a conjugate of claim 37 and one or more reagents for detecting angiogenesis.
44. (Previously presented) A conjugate comprising (a) an scFv antibody with specific, high affinity for the ED-B domain of fibronectin having VH, VL and linker domains with the amino acid sequences encoded, respectively, by the VH-, VL- and linker-DNA of the DNA insert of ATCC deposit no. PTA-9529 and (b) a molecule capable of inducing blood coagulation and blood vessel occlusion.
45. (Currently amended) A conjugate comprising (a) an antibody with specific, high affinity for the ED-B domain of fibronectin and having aVH domain linked to a VL domain, wherein said VH domain has the following amino acid sequence:

VH domain (SEQ ID NO: 30)

EVQLLES GGG	LVQP GGS LRL	SCAAS GFTFS
SF S M S WVRQA	PGK GLEWVSS	ISGSS GTTYY

ADSVKGRFTI      SRDNSKNTLY      LQMNSLRAED  
TAVYYCAKPF      PYFDYWGQGT      LVTVSS,

and (b) a molecule capable of inducing blood coagulation and blood vessel occlusion.